Stay updated on Safety of SNA-120 in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Safety of SNA-120 in Psoriasis Clinical Trial page.

Latest updates to the Safety of SNA-120 in Psoriasis Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2; no study content or user-facing information was changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check28 days agoChange DetectedThe notice about a lapse in government funding and potential delays in updating information was removed from the page.SummaryDifference0.3%

- Check43 days agoChange DetectedThe new screenshot shows only minor formatting and layout adjustments with no changes to core study details such as title, eligibility criteria, interventions, or outcome measures.SummaryDifference0.3%

- Check71 days agoChange Detected- Added a government funding operating-status notice and updated operating details for NIH Clinical Center (high importance). - Updated version from v3.1.0 to v3.2.0 (moderate importance).SummaryDifference4%

- Check78 days agoChange DetectedThe page now shows Revision: v3.1.0 and removes several key safety-related topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) from the content, indicating a narrowing of coverage despite the new version tag.SummaryDifference0.4%

- Check93 days agoChange DetectedRevision updated from v3.0.1 to v3.0.2. The 'Back to Top' element was removed.SummaryDifference0.2%

Stay in the know with updates to Safety of SNA-120 in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of SNA-120 in Psoriasis Clinical Trial page.